微量氨基相关受体1激动剂降低了脑中血清素缺乏的托芬氧化酶2的侵略性,击倒了大鼠
Ilya S Zhukov1,2, Yazen Alnefeesi1, Natalya A Krotova3
1Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.
Frontiers in psychiatry
|January 3, 2025
概括
微氨基关联受体1 (TAAR1) 激动剂可以治疗与血清素 (5-HT) 缺陷相关的侵略性. 向TAAR1降低了被耗尽5-HT的老鼠的攻击性,这表明社会地位的提升是关键的动机.
科学领域:
- 神经科学是一个神经科学.
- 行为科学 行为科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年的侵略和自我伤害与社会地位的担忧和血清素 (5-HT) 缺陷有关.
- 基因模型,如托氧化酶2淘汰 (TPH2-KO) 动物,表现出增加的侵略性,反映了5-HT耗尽效应.
- 微氨基关联受体1 (TAAR1) 功能障碍也会导致类似的攻击性行为.
研究的目的:
- 调查TAAR1激动剂RO5263397是否可以减轻因5-HT耗尽而产生的侵略性.
- 为了确定TPH2-KO大鼠的侵略动机是否是由社会地位的提升驱动的.
主要方法:
- 居民入侵者模式被采用,使用更大和更小的入侵者.
- 模拟5-HT缺乏症的TPH2-KO大鼠进行了攻击性行为测试.
- 评估了TAAR1激动剂RO5263397对侵略性的影响.
主要成果:
- 与对照组相比,缺乏5-HT的老鼠对较小的入侵者没有增加侵略性.
- 当面对更大的入侵者时,TPH2-KO老鼠表现出更高的侵略性和拒绝屈服.
- 在TPH2-KO大鼠中,RO5263397的管理有效地使这种侵略正常化.
结论:
- 社会地位的提升是5-HT贫乏老鼠攻击的重要动机.
- TAAR1代表了一种有前途的治疗点,用于治疗侵略性.
- 这些发现支持开发针对TAAR1通路的新型攻击性治疗方法.
相关概念视频
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...